PMID- 35587323
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220608
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 194
IP  - 1
DP  - 2022 Jul
TI  - Incidence of adverse events with therapies targeting HER2-positive metastatic 
      breast cancer: a literature review.
PG  - 1-11
LID - 10.1007/s10549-021-06469-0 [doi]
AB  - PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted therapies 
      improve survival for patients with HER2-positive breast cancer but carry risks of 
      hematologic, cardiopulmonary, gastro-hepatobiliary, and other adverse events 
      (AEs). In this review, we describe published AE incidences for HER2-targeted 
      therapies for metastatic breast cancer (mBC). METHODS: We searched PubMed and 
      Embase to identify studies on HER2-targeted therapies in HER2-positive mBC, 
      reporting on AEs of special interest, and published between January 1, 2009, and 
      February 6, 2020. Treatment regimens were categorized into mutually exclusive 
      therapy-based categories, with primary therapy determined by worldwide approval 
      date. RESULTS: One hundred and fifty-three included articles assessed a combined 
      29,238 patients treated with the following therapy-based regimens: trastuzumab or 
      biosimilars (78 studies), lapatinib (40), T-DM1 (ado-trastuzumab emtansine) (20), 
      pertuzumab (14), neratinib (8), MM-302 (1), T-DXd (2), tucatinib (3), and 
      pyrotinib (3). While direct comparisons of AE incidence are not warranted owing 
      to study heterogeneity, proportions of patients experiencing any Grade 3 + AE 
      ranged across therapy-based regimens from 39.4% (lapatinib) to 66.3% (neratinib). 
      The most common hematologic AE of special interest, of any grade and regardless 
      of causality, was leukopenia/white blood cells decreased [21.4% (T-DXd)-46.2% 
      (pyrotinib)]. Cardiopulmonary AEs of special interest included interstitial lung 
      disease [2.7% (trastuzumab)-5.2% (T-DXd)], pneumonitis [0.2% (lapatinib)-7.4% 
      (trastuzumab)], and decreased ejection fraction [1% (T-DXd)-13.6% (trastuzumab)]. 
      Gastro-hepatobiliary AEs of special interest included nausea [33.9% 
      (trastuzumab)-78.3% (T-DXd)], vomiting [19.2% (T-DM1)-48.2% (T-DXd)], diarrhea 
      [19.6% (T-DM1)-96.9% (pyrotinib)], and hepatotoxicity [5.9% (lapatinib)-53.6% 
      (T-DM1)]. CONCLUSION: Differing AE profiles for anti-HER2 therapies should be 
      considered when assessing benefit-risk profile for treatment options.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Perez, Edith A
AU  - Perez EA
AUID- ORCID: 0000-0002-5037-6677
AD  - Mayo Clinic, Jacksonville, FL, USA. eaperezmd@gmail.com.
FAU - Dang, Chau
AU  - Dang C
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Lee, Caleb
AU  - Lee C
AD  - Daiichi Sankyo, Basking Ridge, NJ, USA.
FAU - Singh, Jasmeet
AU  - Singh J
AD  - Daiichi Sankyo, Basking Ridge, NJ, USA.
FAU - Wang, Kongming
AU  - Wang K
AD  - Daiichi Sankyo, Basking Ridge, NJ, USA.
FAU - Layton, J Bradley
AU  - Layton JB
AD  - RTI Health Solutions, Research Triangle Park, NC, USA.
FAU - Gilsenan, Alicia
AU  - Gilsenan A
AD  - RTI Health Solutions, Research Triangle Park, NC, USA.
FAU - Hackshaw, Michelle D
AU  - Hackshaw MD
AD  - Daiichi Sankyo, Basking Ridge, NJ, USA.
FAU - Cortes, Javier
AU  - Cortes J
AD  - International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, 
      Madrid and Barcelona, Spain.
AD  - Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
AD  - Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA.
AD  - Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad 
      Europea de Madrid, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220519
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0VUA21238F (Lapatinib)
RN  - 14083FR882 (Maytansine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - SE2KH7T06F (Ado-Trastuzumab Emtansine)
SB  - IM
MH  - Ado-Trastuzumab Emtansine/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Biosimilar Pharmaceuticals/therapeutic use
MH  - *Breast Neoplasms/pathology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Lapatinib/adverse effects
MH  - *Maytansine
MH  - *Neoplasms, Second Primary/etiology
MH  - Receptor, ErbB-2/metabolism
MH  - Trastuzumab
OTO - NOTNLM
OT  - Adverse event
OT  - Safety
OT  - Toxicity
EDAT- 2022/05/20 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/05/19 11:26
PHST- 2021/08/18 00:00 [received]
PHST- 2021/11/27 00:00 [accepted]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/05/19 11:26 [entrez]
AID - 10.1007/s10549-021-06469-0 [pii]
AID - 10.1007/s10549-021-06469-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2022 Jul;194(1):1-11. doi: 10.1007/s10549-021-06469-0. 
      Epub 2022 May 19.